- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07811713
Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension
Effect of Laparoscopy Splenectomy and Azygoportal Disconnectionon Renal Function in Cirrhotic Patients With Portal Hypertension
Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to the kidneys and fluid buildup in the abdomen (ascites). Laparoscopy splenectomy and azygoportal disconnection (LSD) is a minimally invasive surgery commonly used to treat bleeding from swollen veins in these patients, but its impact on kidney function recovery remains unclear.
This study will review medical records of patients with liver cirrhosis and portal hypertension who underwent LSD at our hospital. We will measure kidney function using estimated glomerular filtration rate (eGFR) before surgery and at 3, 6, 9, and 12 months after surgery to evaluate changes over time. We will also examine whether factors such as fluid buildup in the abdomen (ascites) before surgery are associated with kidney function changes after LSD.
The goal is to better understand how LSD affects kidney function in these patients and to identify factors that may predict kidney function recovery, which could help improve care for cirrhotic patients undergoing this surgery.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Liver cirrhosis is associated with systemic hemodynamic disturbances, reduced effective circulating volume, and renal hypoperfusion, creating a high risk of renal dysfunction and hepatorenal syndrome (HRS)-a life-threatening condition reflecting the critical hepatorenal interaction. Patients with cirrhosis and portal hypertension frequently have subclinical or overt renal impairment preoperatively. Laparoscopy splenectomy and azygoportal disconnection (LSD) is a standard intervention for cirrhotic patients with portal hypertension, but its impact on long-term renal function recovery remains unclear.
This single-center retrospective cohort study will be conducted at the Department of Hepatobiliary Surgery, Subei People's Hospital Affiliated to Yangzhou University, Yangzhou, China. We will retrospectively collect clinical and follow-up data from patients with liver cirrhosis and portal hypertension who underwent LSD between February 2012 and February 2025.
Patients will be stratified into two groups based on preoperative estimated glomerular filtration rate (eGFR): impaired renal function group (<90 mL/min/1.73m²) and normal renal function group (≥90 mL/min/1.73m²). Kidney function will be assessed using eGFR calculated with the 2021 CKD-EPI creatinine equation at five time points: preoperative baseline and postoperative months 3, 6, 9, and 12.
Statistical analyses will include linear mixed-effects models (LMM) to evaluate eGFR change trajectories and group differences over time; multivariable linear regression to identify factors independently associated with eGFR change (ΔeGFR = postoperative month 12 eGFR - preoperative eGFR); and multivariable logistic regression (limited to patients with baseline eGFR <90 mL/min/1.73m²) to identify predictors of renal function recovery to normal (eGFR ≥90 mL/min/1.73m²).
The study aims to evaluate whether LSD is associated with kidney function improvement in patients with liver cirrhosis and portal hypertension, whether the degree of improvement differs between patients with and without pre-existing renal impairment, and whether preoperative factors such as ascites severity are associated with the magnitude of renal function recovery. These findings may help fill an important gap in understanding the hepatorenal axis after LSD and guide perioperative renal protection strategies in this high-risk population.
Type d'étude
Inscription (Réel)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Age ≥18 years.
- Diagnosis of liver cirrhosis with portal hypertension.
- Underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at our institution.
- Adequate preoperative and postoperative clinical and follow-up data for analysis.
- Preoperative and postoperative eGFR data available at the specified time points (baseline, month 3, 6, 9, and 12).
Exclusion Criteria:
- Child-Pugh Class C liver cirrhosis.
- Primary renal diseases (e.g., glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.).
- Previous abdominal surgery that precluded safe laparoscopic splenectomy and azygoportal disconnection (LSD).
- Severe cardiac, pulmonary, or cerebrovascular dysfunction; malignant tumors; or primary hematological disorders.
- Hepatic encephalopathy or refractory ascites within 1 month before surgery.
- Pregnancy or lactation.
- Poor compliance or inability to complete follow-up.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
LSD-treated Patients with Liver Cirrhosis and Portal Hypertension
Patients who underwent laparoscopy splenectomy and azygoportal disconnection for liver cirrhosis with portal hypertension
|
A minimally invasive surgical procedure involving laparoscopic removal of the spleen and ligation of perigastric and esophageal varices to reduce portal hypertension and prevent variceal bleeding.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Serum Creatinine (Scr) Level
Délai: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Change in serum creatinine (Scr) level, used for eGFR calculation.
|
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
|
Estimated Glomerular Filtration Rate (eGFR)
Délai: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Change in estimated glomerular filtration rate (eGFR) calculated using the 2021 CKD-EPI creatinine equation.
eGFR was assessed at preoperative baseline and postoperative months 3, 6, 9, and 12 to evaluate longitudinal renal function changes.
|
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Blood Urea Nitrogen (BUN) Level
Délai: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Changes in BUN level as additional indicators of renal function.
|
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
|
Blood Uric Acid (UA) Level
Délai: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Changes in UA level as additional indicators of renal function.
|
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
|
Postoperative Complications
Délai: At postoperative day 1, day 3, day 7, month 1, month 3, month 6, month 12
|
Postoperative complications including bleeding, infection, hepatic encephalopathy, and ascites.
|
At postoperative day 1, day 3, day 7, month 1, month 3, month 6, month 12
|
|
Albumin
Délai: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Changes in serum albumin levels.
|
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
|
Total Bilirubin Level
Délai: At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Changes in serum total bilirubin levels.
|
At preoperative baseline, postoperative month 3, month 6, month 9, month 12
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: guoqing jiang, Clinical Medical College, Yangzhou University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- YZUC-025
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .